Free Trial

PureTech Health (PRTC) Competitors

PureTech Health logo
GBX 142 -4.00 (-2.74%)
As of 02/21/2025 11:46 AM Eastern

PRTC vs. ONT, GNS, ERGO, SLN, OXB, HZD, VRP, FARN, ARIX, and BVXP

Should you be buying PureTech Health stock or one of its competitors? The main competitors of PureTech Health include Oxford Nanopore Technologies (ONT), Genus (GNS), Ergomed (ERGO), Silence Therapeutics (SLN), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Verona Pharma plc (VRP.L) (VRP), Faron Pharmaceuticals Oy (FARN), Arix Bioscience (ARIX), and Bioventix (BVXP). These companies are all part of the "biotechnology" industry.

PureTech Health vs.

PureTech Health (LON:PRTC) and Oxford Nanopore Technologies (LON:ONT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, community ranking, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

In the previous week, PureTech Health had 2 more articles in the media than Oxford Nanopore Technologies. MarketBeat recorded 2 mentions for PureTech Health and 0 mentions for Oxford Nanopore Technologies. PureTech Health's average media sentiment score of 0.34 beat Oxford Nanopore Technologies' score of 0.00 indicating that PureTech Health is being referred to more favorably in the media.

Company Overall Sentiment
PureTech Health Neutral
Oxford Nanopore Technologies Neutral

Oxford Nanopore Technologies has a net margin of -94.82% compared to PureTech Health's net margin of -17,620.94%. PureTech Health's return on equity of -21.15% beat Oxford Nanopore Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
PureTech Health-17,620.94% -21.15% -13.39%
Oxford Nanopore Technologies -94.82%-26.02%-14.42%

PureTech Health received 497 more outperform votes than Oxford Nanopore Technologies when rated by MarketBeat users. However, 100.00% of users gave Oxford Nanopore Technologies an outperform vote while only 86.60% of users gave PureTech Health an outperform vote.

CompanyUnderperformOutperform
PureTech HealthOutperform Votes
530
86.60%
Underperform Votes
82
13.40%
Oxford Nanopore TechnologiesOutperform Votes
33
100.00%
Underperform Votes
No Votes

PureTech Health has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Oxford Nanopore Technologies has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.

PureTech Health presently has a consensus target price of GBX 455, indicating a potential upside of 220.42%. Oxford Nanopore Technologies has a consensus target price of GBX 235.50, indicating a potential upside of 101.63%. Given PureTech Health's higher possible upside, research analysts plainly believe PureTech Health is more favorable than Oxford Nanopore Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PureTech Health
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Oxford Nanopore Technologies
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

79.9% of PureTech Health shares are held by institutional investors. Comparatively, 38.4% of Oxford Nanopore Technologies shares are held by institutional investors. 15.9% of PureTech Health shares are held by insiders. Comparatively, 32.6% of Oxford Nanopore Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

PureTech Health has higher earnings, but lower revenue than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PureTech Health£521.32K818.19-£91.86M-£24.38-5.83
Oxford Nanopore Technologies£184.78M6.00-£175.21M-£18.58-6.29

Summary

PureTech Health beats Oxford Nanopore Technologies on 11 of the 17 factors compared between the two stocks.

Get PureTech Health News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRTC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PRTC vs. The Competition

MetricPureTech HealthBiotechnology IndustryMedical SectorLON Exchange
Market Cap£426.54M£117.96M£5.77B£2.60B
Dividend YieldN/A3.69%4.78%5.04%
P/E Ratio-5.833.2026.46162.81
Price / Sales818.194,828.14455.02309,391.95
Price / Cash2.1413.0144.0427.80
Price / Book1.2547.077.635.11
Net Income-£91.86M-£87.82M£3.18B£5.68B
7 Day Performance-2.74%0.36%-1.91%-1.09%
1 Month Performance2.90%3.63%-0.19%-0.84%
1 Year Performance-25.81%99.12%16.70%39.59%

PureTech Health Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRTC
PureTech Health
2.0226 of 5 stars
GBX 142
-2.7%
GBX 455
+220.4%
-24.1%£426.54M£521,320.79-5.83300News Coverage
ONT
Oxford Nanopore Technologies
1.8749 of 5 stars
GBX 126.72
-0.5%
GBX 235.50
+85.8%
-14.8%£1.20B£184.78M-6.821,281
GNS
Genus
1.3657 of 5 stars
GBX 1,806
-1.2%
GBX 2,150
+19.0%
-7.1%£1.18B£666.67M149.70480Gap Down
ERGO
Ergomed
N/AN/AN/AN/A£701.00M£152.09M4,641.386
SLN
Silence Therapeutics
N/AN/AN/AN/A£480.35M£11.35M-11.01100High Trading Volume
OXB
Oxford Biomedica
2.5294 of 5 stars
GBX 387
-0.5%
GBX 433.33
+12.0%
+102.0%£411.39M£98.31M-2.88891News Coverage
Gap Down
HZD
Horizon Discovery Group plc (HZD.L)
N/AN/AN/AN/A£302.98M£54.63M-33.55416
VRP
Verona Pharma plc (VRP.L)
N/AN/AN/AN/A£228MN/A-1.6822Gap Up
FARN
Faron Pharmaceuticals Oy
N/AGBX 168.50
+0.6%
N/A+32.3%£226.21MN/A-4.5134Gap Up
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919
BVXP
Bioventix
N/AGBX 2,900
-0.9%
N/A-41.7%£151.85M£13.65M18.7612Negative News

Related Companies and Tools


This page (LON:PRTC) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners